^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Ca2+ channel antagonist

    Related drugs:
    6d
    A clinical trial of Tetrandrine Tablets in combination with Mitotane for the treatment of mitotane-resistant advanced adrenocortical carcinom (ChiCTR2500113189)
    P=N/A, N=62, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    Lysodren (mitotane) • CBT-1 (tetrandrine)
    6d
    Efficacy and safety of Tetrandrine in the treatment of herpes zoster-associated pain (ZAP):A randomized, double-blind, placebo-controlled multicenter trial (ChiCTR2500112471)
    P4, N=240, Not yet recruiting, China-Japan Friendship Hospital; ZHEJIANG JINHUA CONBA BIO-PHARM.CO.,LTD.
    New P4 trial
    |
    CBT-1 (tetrandrine)
    6d
    A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • hydroxychloroquine • tofacitinib • CBT-1 (tetrandrine)
    9d
    Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    papaverine
    14d
    NEPHRON: Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, The Cleveland Clinic
    New trial
    15d
    Dual Potential of Tetrandrine: Antiangiogenic Efficacy and Safety Liabilities Revealed through In Silico, In Vitro, and Zebrafish Models. (PubMed, Food Chem Toxicol)
    These findings highlight tetrandrine's dual profile: a promising natural antiangiogenic agent with demonstrable efficacy, yet with significant cardiotoxic and developmental liabilities. This study provides crucial mechanistic insight into both its therapeutic and toxicological actions, establishing a translational foundation for its further development.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • SRPK1 (SRSF Protein Kinase 1)
    |
    CBT-1 (tetrandrine)
    21d
    Targeting ferroptosis by trimetazidine and probiotics to attenuate 5-fluorouracil-induced intestinal mucositis in mice. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    The combination also provided additional improvement in intestinal structure (villus height, crypt depth, and enteritis score) compared with each monotherapy group. Either trimetazidine or probiotics alleviated 5-FU-induced intestinal mucositis and might be considered promising candidates for preventing CIM by anti-inflammatory, antioxidant, and mechanisms associated with modulation of ferroptosis-related pathways.
    Preclinical • Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • IL1B (Interleukin 1, beta)
    |
    5-fluorouracil
    23d
    ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Milestone Pharmaceuticals Inc. | Trial completion date: Jan 2029 --> Jan 2030 | Trial primary completion date: Jan 2028 --> Jan 2029
    Trial completion date • Trial primary completion date
    28d
    Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction (clinicaltrials.gov)
    P=N/A, N=194, Completed, Chinese PLA General Hospital
    New trial
    29d
    Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases (clinicaltrials.gov)
    P1, N=27, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial primary completion date
    |
    papaverine
    1m
    A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease (clinicaltrials.gov)
    P4, N=100, Recruiting, Peking University Third Hospital
    New P4 trial
    |
    CBT-1 (tetrandrine)
    2ms
    NILOS: Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Cardarelli Hospital
    New trial